Drugs / Microtransplantation
Microtransplantation
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03920631 | Jul 2020 → Mar 2023 | B-cell non-Hodgkin lymphoma | Ahmed Galal, MD | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01674985 | Sep 2009 → Oct 2013 | myelodysplastic syndrome | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02831192 | May 2006 → Jul 2015 | acute myeloid leukemia | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02461121 | May 2004 → May 2013 | acute myeloid leukemia | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Microtransplantation | “Biological: Microtransplantation” NCT03920631 ↗ |
| Known as | HLA mismatched stem cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02461121 ↗ |
| Known as | MST | “The purpose of this study is to see whether HLA-mismatched donor cells infusion with chemotherapy (microtransplantation，MST) could increase complete remission (CR) and improve...” NCT02831192 ↗ |
| Modality | Cell therapy | “Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)” NCT01674985 ↗ |
| Route | Other | “HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy” NCT02461121 ↗ |